Annual Current Liabilities
$5.12 M
+$549.00 K+12.00%
March 31, 2024
Summary
- As of March 7, 2025, VTGN annual total current liabilities is $5.12 million, with the most recent change of +$549.00 thousand (+12.00%) on March 31, 2024.
- During the last 3 years, VTGN annual current liabilities has risen by +$934.00 thousand (+22.30%).
- VTGN annual current liabilities is now -70.54% below its all-time high of $17.39 million, reached on March 31, 2015.
Performance
VTGN Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$9.62 M
+$2.10 M+27.89%
December 31, 2024
Summary
- As of March 7, 2025, VTGN quarterly total current liabilities is $9.62 million, with the most recent change of +$2.10 million (+27.89%) on December 31, 2024.
- Over the past year, VTGN quarterly current liabilities has increased by +$3.38 million (+54.28%).
- VTGN quarterly current liabilities is now -44.67% below its all-time high of $17.39 million, reached on March 31, 2015.
Performance
VTGN Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
VTGN Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +12.0% | +54.3% |
| 3 y3 years | +22.3% | +54.3% |
| 5 y5 years | +82.9% | +54.3% |
VTGN Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -11.1% | +22.3% | at high | +230.7% |
| 5 y | 5-year | -11.1% | +84.9% | at high | +259.9% |
| alltime | all time | -70.5% | >+9999.0% | -44.7% | >+9999.0% |
VistaGen Therapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $9.62 M(+27.9%) |
| Sep 2024 | - | $7.52 M(+20.6%) |
| Jun 2024 | - | $6.24 M(+21.7%) |
| Mar 2024 | $5.12 M(+12.0%) | $5.12 M(+23.0%) |
| Dec 2023 | - | $4.16 M(+43.1%) |
| Sep 2023 | - | $2.91 M(-28.1%) |
| Jun 2023 | - | $4.05 M(-11.5%) |
| Mar 2023 | $4.57 M(-20.7%) | $4.57 M(+6.7%) |
| Dec 2022 | - | $4.29 M(-29.1%) |
| Sep 2022 | - | $6.05 M(-32.3%) |
| Jun 2022 | - | $8.93 M(+54.8%) |
| Mar 2022 | $5.77 M(+37.6%) | $5.77 M(-10.2%) |
| Dec 2021 | - | $6.42 M(-18.8%) |
| Sep 2021 | - | $7.91 M(+26.3%) |
| Jun 2021 | - | $6.27 M(+49.6%) |
| Mar 2021 | $4.19 M(+51.2%) | $4.19 M(+40.5%) |
| Dec 2020 | - | $2.98 M(-9.7%) |
| Sep 2020 | - | $3.30 M(+23.5%) |
| Jun 2020 | - | $2.67 M(-3.5%) |
| Mar 2020 | $2.77 M(-1.1%) | $2.77 M(-5.6%) |
| Dec 2019 | - | $2.94 M(-28.7%) |
| Sep 2019 | - | $4.12 M(+24.4%) |
| Jun 2019 | - | $3.31 M(+18.1%) |
| Mar 2019 | $2.80 M(+92.0%) | $2.80 M(+42.5%) |
| Dec 2018 | - | $1.97 M(+50.3%) |
| Sep 2018 | - | $1.31 M(-30.1%) |
| Jun 2018 | - | $1.87 M(+28.3%) |
| Mar 2018 | $1.46 M(+6.7%) | $1.46 M(+10.0%) |
| Dec 2017 | - | $1.33 M(-29.6%) |
| Sep 2017 | - | $1.88 M(+87.5%) |
| Jun 2017 | - | $1.00 M(-26.5%) |
| Mar 2017 | $1.37 M | $1.37 M(-27.0%) |
| Dec 2016 | - | $1.87 M(+4.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $1.80 M(+12.2%) |
| Jun 2016 | - | $1.60 M(-10.8%) |
| Mar 2016 | $1.79 M(-89.7%) | $1.79 M(-14.6%) |
| Dec 2015 | - | $2.10 M(-10.5%) |
| Sep 2015 | - | $2.35 M(-28.4%) |
| Jun 2015 | - | $3.28 M(-81.1%) |
| Mar 2015 | $17.39 M(+234.0%) | $17.39 M(+61.5%) |
| Dec 2014 | - | $10.76 M(+56.1%) |
| Sep 2014 | - | $6.89 M(+11.2%) |
| Jun 2014 | - | $6.20 M(+19.0%) |
| Mar 2014 | $5.21 M(+115.6%) | $5.21 M(+40.2%) |
| Dec 2013 | - | $3.71 M(+14.1%) |
| Sep 2013 | - | $3.25 M(+10.9%) |
| Jun 2013 | - | $2.93 M(+21.5%) |
| Mar 2013 | $2.41 M(-24.1%) | $2.41 M(-6.3%) |
| Dec 2012 | - | $2.58 M(-12.5%) |
| Sep 2012 | - | $2.94 M(-32.8%) |
| Jun 2012 | - | $4.39 M(+37.8%) |
| Mar 2012 | $3.18 M(>+9900.0%) | $3.18 M(+43.5%) |
| Dec 2011 | - | $2.22 M(-64.2%) |
| Sep 2011 | - | $6.20 M(+11.8%) |
| Jun 2011 | - | $5.54 M(>+9900.0%) |
| Mar 2011 | - | $6700.00(+109.4%) |
| Dec 2010 | $3200.00(+113.3%) | $3200.00(-5.9%) |
| Sep 2010 | - | $3400.00(+126.7%) |
| Jun 2010 | - | $1500.00(-64.3%) |
| Mar 2010 | - | $4200.00(+180.0%) |
| Dec 2009 | $1500.00(-44.4%) | $1500.00(-44.4%) |
| Sep 2009 | - | $2700.00(+80.0%) |
| Jun 2009 | - | $1500.00(-44.4%) |
| Dec 2008 | $2700.00 | $2700.00(-27.0%) |
| Jun 2008 | - | $3700.00(+37.0%) |
| Mar 2008 | - | $2700.00 |
FAQ
- What is VistaGen Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual current liabilities year-on-year change?
- What is VistaGen Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly current liabilities year-on-year change?
What is VistaGen Therapeutics annual total current liabilities?
The current annual current liabilities of VTGN is $5.12 M
What is the all time high annual current liabilities for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual total current liabilities is $17.39 M
What is VistaGen Therapeutics annual current liabilities year-on-year change?
Over the past year, VTGN annual total current liabilities has changed by +$549.00 K (+12.00%)
What is VistaGen Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of VTGN is $9.62 M
What is the all time high quarterly current liabilities for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly total current liabilities is $17.39 M
What is VistaGen Therapeutics quarterly current liabilities year-on-year change?
Over the past year, VTGN quarterly total current liabilities has changed by +$3.38 M (+54.28%)